These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1288 related items for PubMed ID: 17984104

  • 1. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
    Zeltner R, Poliak R, Stiasny B, Schmieder RE, Schulze BD.
    Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
    [Abstract] [Full Text] [Related]

  • 2. Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease.
    Steinman TI.
    Nephrol Dial Transplant; 2008 Feb; 23(2):431-3. PubMed ID: 18065782
    [No Abstract] [Full Text] [Related]

  • 3. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD, Mion D, Rocha JC, Kohlmann O, Gomes MA, Saraiva JF, Amodeo C, Filho BL.
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [Abstract] [Full Text] [Related]

  • 4. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients.
    Suwelack B, Kobelt V, Erfmann M, Hausberg M, Gerhardt U, Rahn KH, Hohage H.
    Transpl Int; 2003 May; 16(5):313-20. PubMed ID: 12759722
    [Abstract] [Full Text] [Related]

  • 5. Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertension. Addition of felodipine or ramipril to long-term treatment with beta-blockade.
    Siewert-Delle A, Ljungman S, Hartford M, Wikstrand J.
    Am J Hypertens; 1995 Feb; 8(2):113-23. PubMed ID: 7755939
    [Abstract] [Full Text] [Related]

  • 6. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, Holdaas H, Krcmery S, Kobalava Z, Amlodipine Versus Enalapril in Renal failure (AVER) Study Group.
    Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
    [Abstract] [Full Text] [Related]

  • 7. Mechanical vs intrinsic components in the improvement of brachial arterial compliance. Comparison of the effects of atenolol versus ramipril in hypertensive patients.
    Armentano RL, Graf S, Ramírez AJ, Espinosa JD, Brandani L, Baglivo H, Sánchez R.
    Medicina (B Aires); 2001 Mar; 61(5 Pt 1):535-40. PubMed ID: 11721319
    [Abstract] [Full Text] [Related]

  • 8. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.
    Arch Intern Med; 2005 Apr 25; 165(8):936-46. PubMed ID: 15851647
    [Abstract] [Full Text] [Related]

  • 9. Hypertension in autosomal dominant polycystic kidney disease: observational study in 207 patients with a mean follow-up of 107 months.
    De Almeida EA, Prata MM.
    Rev Port Cardiol; 2007 Nov 25; 26(11):1173-82. PubMed ID: 18297839
    [Abstract] [Full Text] [Related]

  • 10. A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease.
    Ulusoy S, Ozkan G, Orem C, Kaynar K, Koşucu P, Kiriş A.
    Ren Fail; 2010 Nov 25; 32(8):913-7. PubMed ID: 20722556
    [Abstract] [Full Text] [Related]

  • 11. [Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors].
    Erley CM, Berger ED, Heyne N, Klass M, Krämer D, Braun N, Wolf S, Risler T.
    Dtsch Med Wochenschr; 1997 Aug 01; 122(31-32):953-8. PubMed ID: 9280714
    [Abstract] [Full Text] [Related]

  • 12. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy.
    Salako BL, Finomo FO, Kadiri S, Arije A, Olatosin AO.
    Afr J Med Med Sci; 2002 Mar 01; 31(1):53-7. PubMed ID: 12518931
    [Abstract] [Full Text] [Related]

  • 13. Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis.
    Erley CM, Klass M, Krämer D, Berger E, Heyne N, Braun N, Wolf S, Risler T.
    Int J Clin Pharmacol Ther; 1996 Nov 01; 34(11):504-9. PubMed ID: 8937934
    [Abstract] [Full Text] [Related]

  • 14. Vasopeptidase inhibition prevents target organ damage and improves survival in spontaneously hypertensive rats.
    Linz W, Schäfer S, Afkham F, Gerl M, Schmidts HL, Rütten H.
    J Renin Angiotensin Aldosterone Syst; 2006 Sep 01; 7(3):155-61. PubMed ID: 17094052
    [Abstract] [Full Text] [Related]

  • 15. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 01; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 16. Strict blood-pressure control and progression of renal failure in children.
    ESCAPE Trial Group, Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Möller K, Wigger M, Peruzzi L, Mehls O, Schaefer F.
    N Engl J Med; 2009 Oct 22; 361(17):1639-50. PubMed ID: 19846849
    [Abstract] [Full Text] [Related]

  • 17. Long-term renal function in primary hypertension. An epidemiological and pathophysiological study.
    Siewert-Delle A.
    Scand J Urol Nephrol Suppl; 1999 Oct 22; 199():1-36. PubMed ID: 10349677
    [Abstract] [Full Text] [Related]

  • 18. Determinants of urinary albumin excretion reduction in essential hypertension: A long-term follow-up study.
    Pascual JM, Rodilla E, Miralles A, Gonzalez C, Redon J.
    J Hypertens; 2006 Nov 22; 24(11):2277-84. PubMed ID: 17053551
    [Abstract] [Full Text] [Related]

  • 19. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
    Ishimitsu T, Honda T, Ohta S, Akashiba A, Takahashi T, Kameda T, Yoshii M, Minami J, Takahashi M, Ono H, Matsuoka H.
    Am J Hypertens; 2006 Dec 22; 19(12):1233-40. PubMed ID: 17161768
    [Abstract] [Full Text] [Related]

  • 20. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
    Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG, African American Study of Kidney Disease and Hypertension Study Group.
    JAMA; 2002 Nov 20; 288(19):2421-31. PubMed ID: 12435255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.